Xponent.ppt

2010 IMS HEALTH Confidential
1
Expand your decision making scope
`
Xponent

2
Agenda
What is Xponent?
Prescription Panel & Data Collection
• How we collect, what we collect & who we collect from
Xponent Project methodology
• What it is, why it is important and how it brings value
Quantiling & Aggregation
• Why is it necessary, how is it done
Confidentiality Requirements
• How we safeguard the data source

3
• Xponent is customized to the clients’ markets and sales force
alignments.
• Xponent allows for tracking the aggregated dispensed
prescriptions back to the prescriber.
• Xponent data includes the most current 24 months.
• Xponent is available in six provinces:
What is Xponent?
• Alberta • Saskatchewan
• Ontario • Quebec
• New Brunswick • Nova Scotia

4
Pharmaceutical Manufacturers use Xponent to:
• Segment Prescribers into priority groups (Key)
• Identify differences in information needs for each
segment
• Deliver information that brings value to the Prescriber
• Allocate their efforts to the priority Prescribers
• Assess impact
Why use Xponent?
“See the Right customer, the Right number
of times and deliver the Right message”

5
Xponent
Prescription Panel & Data Collection

6
• There are 6,187 stores in the 6 Xponent provinces
• On a monthly basis, IMS collects prescriptions dispensed data
from ~4,700 Retail stores in the 6 Xponent provinces
• No hospital dispensaries
• Internet pharmacies are excluded from the store panel
• All panel stores submit NRx (new) and RRx (refill) information
• Identity of panel stores is strictly confidential
Xponent
Store Panel & Data Collection

7
IMS captures DISPENSED Prescriptions
Dispensed (filled) Rxs are indicators to the
pharmaceutical manufacturers if their efforts
are successful.
Xponent
Prescription Data Collection

8
Dispensed Rx information is collected from the panel of retail
pharmacies.
The following information is required by Xponent:
• Product name
• Manufacturer name
• Product Form/Strength
• Rx type-New or Refill
• Location of pharmacy
• MD license number
• De-identified Patient Age
• De-identified Patient Gender
Xponent
Data Collection
Same as CompuScript
Used in Xponent

9
Prescriber
• Provincial ID number matched to the IMS doctor
database, FINDr.
• FINDr provides additional information regarding the
prescriber:
 Name, Address, Specialty, Interest, Language preference,
Gender, Grad Year
• Need 1 Rx to have visibility to a Prescriber
Xponent
Data Collection

10
• Raw prescription data go through a projection methodology
that transforms it into reliable estimates of dispensed
prescription activity.
Xponent
Projection Methodology
Xponent is
produced with
monthly.
Raw (or unprojected)
Rx information
received by IMS from
all 5,100 stores.
A geospatial
projection
methodology
transforms the raw
data into reliable
estimates of
prescription
volume.

11
• Projections performed at the product form and strength
level
• A minimum of 1 Rx is required in order to project
Xponent
Projection Methodology

12
Understanding
Quantiling and Aggregation

13
Confidentiality Statement:
All prescriber values are based on
aggregated data of at least 30 prescribers
in order to preserve the anonymity of
individual prescribing behaviour.
Xponent

14
Quantiling (sorting & grouping)
• Divide data into groups containing (as near as
possible) equal numbers of prescriptions
Aggregation (averaging)
• Each group is summed to create a total
• An average is calculated for each group to
confidentialize the number
Xponent

15
• Not all provinces require the same level of
confidentiality
• Quebec’s laws are the most stringent
• Xponent’s confidentiality rules will adhere
to Quebec’s guidelines
Xponent

16
Quantiling:
• Done after projections
• Prescribers are sorted into groups
(quantiles) based on their prescribing
volume
• Minimum of 30 Prescribers
Xponent

17
Quantiling:
• Done at MARKET and PRODUCT (group)
levels
• Done within specified time period
• Quantiling Rules must be met
Xponent

18
Aggregation:
• An average Rx volume is calculated for the
group and assigned to each Prescriber in
that group
Xponent

19
National Groups of 30
&
Provincial Re-Ranking
Xponent

20
National Groups of 30 & Provincial re-rank
• To achieve the most precise average for a
prescriber
• To better identify high prescribers particularly in
smaller provinces
Xponent

21
National Groups of 30 & Provincial Re-Rank
Create Groups of 30 Prescribers
Groups of 30 are created
Prescriber Province Estimated Rx volumes
Dr. QC 1527
Dr. QC 1523
Dr. QC 1521
Dr. ON 1501
Dr. ON 1498
Dr. QC 1498
Dr. QC 1477
Dr. QC 1472
Dr. ON 1470
Dr. ON 1468
Dr. AB 1467
Dr. QC 1462
Dr. ON 1452
Dr. ON 1451
Dr. QC 1451
Dr. QC 1451
Dr. QC 1387
Dr. QC 1387
Dr. ON 1382
Dr. ON 1382
Dr. QC 1380
Dr. QC 1380
Dr. QC 1379
Dr. ON 1375
Dr. ON 1375
Dr. AB 1375
Dr. QC 1374
Dr. ON 1372
Dr. ON 1371
Dr. ON 1368
Dr. QC 1368
Dr. QC 1355
Dr. QC 1345
Dr. ON 1345
Dr. ON 1342
Dr. AB 1342
Dr. QC 1342
Dr. ON 1336
Dr. QC 1336
Dr. QC 1330

22
Calculate Rx average for the group
Calculate the average for the group
Prescriber Province Estimated Rx volumes
Dr. QC 1527
Dr. QC 1523
Dr. QC 1521
Dr. ON 1501
Dr. ON 1498
Dr. QC 1498
Dr. QC 1477
Dr. QC 1472
Dr. ON 1470
Dr. ON 1468
Dr. AB 1467
Dr. QC 1462
Dr. ON 1452
Dr. ON 1451
Dr. QC 1451
Dr. QC 1451
Dr. QC 1387
Dr. QC 1387
Dr. ON 1382
Dr. ON 1382
Dr. QC 1380
Dr. QC 1380
Dr. QC 1379
Dr. ON 1375
Dr. ON 1375
Dr. AB 1375
Dr. QC 1374
Dr. ON 1372
Dr. ON 1371
Dr. ON 1368
Dr. QC 1368
Dr. QC 1355
Dr. QC 1345
Dr. ON 1345
Dr. ON 1342
Dr. AB 1342
Dr. QC 1342
Dr. ON 1336
Dr. QC 1336
Dr. QC 1330

23
Each prescriber in the group is assigned this average
Prescriber Province Estimated Aggregated Rx volumes
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. AB 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. AB 1441
Dr. QC 1441
Dr. ON 1441
Dr. ON 1441
Dr. ON 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1275
Dr. ON 1275
Dr. ON 1275
Dr. AB 1275
Dr. QC 1275
Dr. ON 1275
Dr. QC 1275
Dr. QC 1275
The new average Rx volume is 1,441

24
Re-sort the prescribers in their own province using
new average Rx and create Quantiles (i.e. Deciles)
Prescriber Province Estimated Aggregated Rx volumes
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1441
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1275
Dr. QC 1105
Dr. QC 1105
Dr. QC 1105
Dr. QC 1105
Dr. QC 1105
Dr. QC 1105
Dr. QC 1050
Dr. QC 1050
Dr. QC 1050
Decile 1 (Top 10 % of Rx volume)
Decile 2 (Next 10% of Rx volume)
Decile 3
Decile 4

26
National Centiling and Provincial Re-rank
• Prescribers are sorted in Rx volume
• 100 groups are created, each group contains 1% of the
Rx volume
• An average Rx is calculated for each group and
assigned to the respective prescriber
• Prescribers sorted in their own province
• Quantiles are created
Another option

27
Xponent
National Quantiling
For the total market and for
each product group; the
steps are as follows:
1. Combine the
prescribers from all six
provinces.
2. Sort prescribers by Rx
volume.

28
Xponent
National Quantiling
The next steps:
3. Quantile: Create 100
groups (centiles)
based on Rx volume.
(Minimum of 30
prescribers per group).
4. Create an average for
each group.
C1
C2
C3
C4

29
Here are the next steps:
5. Separate the
prescribers by their
province.
6. Sort prescribers by
Rx volume.
7. Create the deciles.
8. Assign the decile to
the prescriber.
Xponent
Final Xponent report.

30
Xponent
Confidentiality

31
• The IMS HEALTH policy is that all data is
confidential and proprietary to IMS HEALTH
• Any data to be released must meet the
confidentiality guidelines set
• IMS HEALTH, in conjunction with members of
the medical and pharmaceutical community,
has developed strict confidentiality policies and
practices
Xponent
Confidentiality

32
Government
• Provincial guidelines are in place regarding the release of
Prescriber level data and therefore must be adhered to
IMS HEALTH (Guidelines within our organization)
• Employee Confidentiality Agreement
• Quebec HEALTH Information Advisory Board
• Privacy Audit
Suppliers
• IMS HEALTH will maintain the strictest standards of data
security to ensure no breech of confidentiality regarding our
suppliers
Xponent
Confidentiality

33
Prescribers
IMS HEALTH must ensure that the confidentiality of each
Prescribers’ true volume is preserved
Confidentiality is ensured by
• Aggregation
• Opt-Out (Quebec only)
Xponent
Confidentiality - Prescribers

34
• A physician can have their name withdrawn from the Xponent reports
• Effective September 2003, IMS has restricted this option to physicians
in Quebec only
• Requests to opt-out prior to September 2003 will continue to be
respected for the physicians in the other provinces
• Effective January 2006, IMS will no longer be allowed to distribute the
Opt-Out list as per request from CAI (Commission d’accès à
l’information)
• Total opt-out to date represents only 2.9% of the total physician
universe
• Majority of Opt-Out physicians are Q3 & Q4 (National ranking)
The Opt Out Prescriber
Xponent
Confidentiality – Prescribers

35
Xponent
Confidentiality - Prescribers
• Prescribers who opt-out have two options:
• Non-Disclosure: The prescriber name and any other
identifying elements are excluded from Xponent reports.
However, their data will be used within Xponent
anonymously.
• Non-Conservation: Everything related to the prescriber is
removed from Xponent
IMS is not allowed to inform you of which option a
prescriber has selected.
IMS is not allowed to identify if a prescriber has opted
out.

36
Xponent
Some Common Questions Answered

37
If a prescriber has multiple addresses, where does the
prescriber’s activity show?
The prescribers’ primary call address is
used.
Xponent
Some Common Questions

38
I noticed in my Xponent report that a prescriber has a higher
Rx volume for my product than for the market. Is this
possible?
Yes. Since the market and each defined
product group are aggregated
individually, it is possible for the
prescriber to be part of a group of
prescribers that through aggregation
caused the number for the product group
to be higher than the market.
Xponent

39
A prescriber is not in my Xponent report. What are the
possible reasons for this?
• The prescriber may have opted-out.
• The prescriber may have moved to another province:
• If this is an Xponent province, the prescriber will
appear in another provincial territory.
• If this is a non-Xponent province, the prescriber will no
longer appear.
• The prescribers’ prescriptions may all be dispensed within
a hospital.
• The store may no longer be part of the IMS store panel
and the prescribers’ total activity was in that store.
Xponent

40
What happens in rural areas when all of a prescriber's
prescriptions come out of one store?
When all of a prescriber’s prescriptions
are filled at one store and the store does
not provide IMS any data, then the
prescriber will not appear in Xponent.
Should the store become a sample store
at some time, then the prescriber will
appear.
Xponent

41
What happens to the prescription volume of retired or
deceased prescribers?
The prescribers’ dispensed prescription
activity will still be tracked due to refills.
Eventually these prescriptions will cease.
Xponent

42
Can a prescriber have access to the data from IMS?
Yes. Prescribers can have access to their
prescribing profile by contacting IMS. The
information provided is a comparison to
their peers and will not be related to your
data as you see it.
Xponent

43
Thank you

Xponent.ppt

Recommended

Recommended

More Related Content

Similar to Xponent.ppt

Similar to Xponent.ppt (20)

Recently uploaded

Recently uploaded (20)

Xponent.ppt